11
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Sex and Gender in Neurodegenerative Diseases

      Submit here before September 30, 2024

      About Neurodegenerative Diseases: 3.0 Impact Factor I 4.3 CiteScore I 0.695 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Distribution of Thyrotropin-Releasing Hormone (TRH) Immunoreactivity in the Brain of Urodele Amphibians

      review-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To improve knowledge of the peptidergic systems in the brain of amphibians we have conducted a comparative analysis of the distribution of TRH immunoreactive cell bodies and fibers in three species of urodeles. Fiber labeling was observed in all main brain subdivisions suggesting different control functions for TRH in extrahypothalamic systems. However, as in other vertebrates, TRH neurons were abundant in the hypothalamic nuclei that presumably project to the median eminence and the neural lobe of the hypophysis. Considerable interspecies differences were noted mainly related to innervation of the olfactory and visual centers (thalamus and mesencephalic tectum) and the precise localization of immunoreactive cell bodies, which was assessed by double labeling with tyrosine hydroxylase. The comparison of the distribution of TRH immunoreactive neurons and fibers found in urodeles with those reported for other vertebrates, in particular with anamniotes, reveals a strong resemblance but also notable variations not only across vertebrate classes but also within the same class. In this respect, the virtual lack in urodeles of TRH innervation of the intermediate lobe of the hypophysis clearly contrasts with the innervation found in anurans. Therefore, the important role of skin color adaptation proposed for TRH in anurans on the basis of the direct innervation of the intermediate lobe is not applicable for urodeles.

          Related collections

          Most cited references83

          • Record: found
          • Abstract: found
          • Article: not found

          Generation of insulin-secreting islet-like clusters from human skin fibroblasts.

          Increasing evidence suggests that islet cell transplantation for patients with type I diabetes holds great promise for achieving insulin independence. However, the extreme shortage of matched organ donors and the necessity for chronic immunosuppression has made it impossible for this treatment to be used for the general diabetic population. Recent success in generating insulin-secreting islet-like cells from human embryonic stem (ES) cells, in combination with the success in deriving human ES cell-like induced pluripotent stem (iPS) cells from human fibroblasts by defined factors, have raised the possibility that patient-specific insulin-secreting islet-like cells might be derived from somatic cells through cell fate reprogramming using defined factors. Here we confirm that human ES-like iPS cells can be derived from human skin cells by retroviral expression of OCT4, SOX2, c-MYC, and KLF4. Importantly, using a serum-free protocol, we successfully generated insulin-producing islet-like clusters (ILCs) from the iPS cells under feeder-free conditions. We demonstrate that, like human ES cells, skin fibroblast-derived iPS cells have the potential to be differentiated into islet-like clusters through definitive and pancreatic endoderm. The iPS-derived ILCs not only contain C-peptide-positive and glucagon-positive cells but also release C-peptide upon glucose stimulation. Thus, our study provides evidence that insulin-secreting ILCs can be generated from skin fibroblasts, raising the possibility that patient-specific iPS cells could potentially provide a treatment for diabetes in the future.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Photodynamic therapy with endogenous protoporphyrin

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Photodynamic therapy in oncology: mechanisms and clinical use.

              In photodynamic therapy (PDT), a sensitizer, light, and oxygen are used to cause photochemically induced cell death. The mechanism of cytotoxicity involves generation of singlet oxygen and other free radicals when the light-excited sensitizer loses or accepts an electron. Although selective retention of sensitizer by malignant tissue is seen in vivo, the mechanisms for this sensitizer targeting remain unclear. The first-generation sensitizers are porphyrin based and vary in lipophilicity and hydrophilicity. Targeting of the vasculature seems to be a prominent feature of the cytotoxic effect of these sensitizers in vivo, with resulting necrosis. Treatment depth varies with the wavelength of light that activates the sensitizer used, and the second-generation sensitizers are activated at longer wavelengths, allowing for a 30% increase in treatment depths. The selectivity of targeting can be increased when the sensitizer is delivered with the use of liposomes or monoclonal antibodies specific for tumor antigens. Studies have demonstrated direct effects of PDT on immune effector cells, specifically those with lineage from macrophages or other monocytes. Clinically, this therapy has been chiefly used for palliation of endobronchial and esophageal obstruction, as well as for treatment of bladder carcinomas, skin malignancies, and brain tumors. The future of PDT rests in defining its use either as an intraoperative adjuvant to marginal surgical procedures or as a primary treatment for superficial malignancies. Phase III trials in esophageal cancer and lung cancer are in progress and will help in evaluation of whether Photofrin II, the most widely used sensitizer, can be added to the oncologic armamentarium, pending approval from the U.S. Food and Drug Administration.
                Bookmark

                Author and article information

                Journal
                BBE
                Brain Behav Evol
                10.1159/issn.0006-8977
                Brain, Behavior and Evolution
                S. Karger AG
                0006-8977
                1421-9743
                2008
                April 2008
                02 April 2008
                : 71
                : 3
                : 231-246
                Affiliations
                Departamento de Biología Celular, Facultad de Biología, Universidad Complutense, Madrid, Spain
                Article
                122835 Brain Behav Evol 2008;71:231–246
                10.1159/000122835
                18382103
                ec8ecfba-6b04-457d-9392-fca6e5378c78
                © 2008 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 19 November 2007
                : 14 January 2008
                Page count
                Figures: 4, Tables: 1, References: 100, Pages: 16
                Categories
                Original Paper

                Geriatric medicine,Neurology,Cardiovascular Medicine,Neurosciences,Clinical Psychology & Psychiatry,Public health
                Immunohistochemistry,TRH,Tyrosine hydroxylase,Preoptic area,Hypothalamus,Hypophysis,Urodeles,Evolution

                Comments

                Comment on this article